These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The influence of the immunosuppressants OKT3 and ATG on immunological parameters. Neumann MC; Müller TF; Sprenger H; Gemsa D; Lange H Clin Nephrol; 1996 May; 45(5):345-8. PubMed ID: 8738669 [TBL] [Abstract][Full Text] [Related]
7. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3). Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870 [No Abstract] [Full Text] [Related]
8. Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection. Jeffrey RF; Johnson MH; Bamford JM; Giles GR; Brownjohn AM; Will EJ Transplantation; 1993 Mar; 55(3):677-9. PubMed ID: 8456493 [No Abstract] [Full Text] [Related]
10. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506 [TBL] [Abstract][Full Text] [Related]
11. Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects. Brown M; Korb S; Light JA; Light T; Jonsson J; Aquino A Transplant Proc; 1993 Feb; 25(1 Pt 1):553-5. PubMed ID: 8438411 [No Abstract] [Full Text] [Related]
12. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients. Thistlethwaite JR; Heffron TG; Stuart JK; Buckingham M; Stuart FP Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):28-34. PubMed ID: 2510508 [TBL] [Abstract][Full Text] [Related]
13. Immunologic monitoring with Orthoclone OKT3 therapy. Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358 [TBL] [Abstract][Full Text] [Related]
14. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163 [TBL] [Abstract][Full Text] [Related]
15. Monitoring of heart allograft rejection by simultaneous measurement of serum beta 2-microglobulin and urinary neopterin. Schmitt F; Myara I; Benoit MO; Guillemain R; Amrein C; Dreyfus G; Paris M; Moatti N Ann Biol Clin (Paris); 1989; 47(5):237-41. PubMed ID: 2662838 [TBL] [Abstract][Full Text] [Related]
16. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial. Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510 [TBL] [Abstract][Full Text] [Related]
17. [Use of OKT-3 in treatment of rejection following kidney transplantation]. Hansen C; Müller P; Seibt F; Oesterwitz H; May G; Strobelt V; Kaden J; Ditscherlein G; Scholz D Z Urol Nephrol; 1990 Apr; 83(4):165-70. PubMed ID: 2116055 [TBL] [Abstract][Full Text] [Related]
18. Visual loss complicating OKT3 monoclonal antibody therapy in a renal transplant recipient. Jin DC; Kim SY; Lee JM; Koo WS; Choi EJ; Yoon YS; Bang BK Nephrol Dial Transplant; 1995 Nov; 10(11):2144-6. PubMed ID: 8643188 [No Abstract] [Full Text] [Related]
19. Neopterin excretion after liver transplantation and its value in differential diagnosis of complications. Tilg H; Vogel W; Aulitzky WE; Schönitzer D; Margreiter R; Dietze O; Judmaier G; Wachter H; Huber C Transplantation; 1989 Oct; 48(4):594-9. PubMed ID: 2552627 [TBL] [Abstract][Full Text] [Related]
20. OKT3 in severe early rejection: predictors for reversal in renal transplant recipients. Sumrani N; Delaney V; Rajpoot D; Tejani A; Butt K; Hong J Transplant Proc; 1990 Aug; 22(4):1750-2. PubMed ID: 2117797 [No Abstract] [Full Text] [Related] [Next] [New Search]